Antibody humanisation may be required when your non-human antibody is intended for use in humans, i.e. a therapeutic antibody. Typically you have a murine monoclonal antibody, with the desired properties. The issue is that the human immune system will over time produce human anti-mouse antibodies (HAMA) against this therapeutic murine antibody, inhibiting its effects.
It should be noted that humanisation may not be necessary. If the antibody is a short-term treatment, the antibody has done its job before HAMA is an issue. There are examples of such therapeutic murine monoclonal antibodies.
It may also be that chimerisation of your antibody will be sufficient for the intended purpose. The process of chimerisation - i.e. the splicing of variable regions of the non-human antibody with the human antibody framework - is part of our antibody humanisation strategy.
Once we have obtained a chimeric antibody, and you have determined that it retains the desired properties of the murine antibody, we will proceed with further modifications by CDR grafting techniques.
We offer to perform royalty free humanisation of your antibody, either as a stand-alone service or as part of the monoclonal antibody development service.
Innovagen was founded in 1992. Since then we have been providing the scientific community with high quality research antibodies and their related services. Our experience and dedicated customer service will ensure that your best interests are looked after when you turn to us with your antibody project.
Postal address |
Innovagen AB SE-22370 Lund SWEDEN |
Telephone | |
Switchboard Fax | +46 46 286 20 60 +46 46 18 81 71 |
General information |
In order to provide you with the best online experience this website uses cookies. By using our website, you agree to our use of cookies. More information available here.